Assenagon Asset Management S.A. Sells 59,138 Shares of Amgen Inc. $AMGN

Assenagon Asset Management S.A. cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 26.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 163,165 shares of the medical research company’s stock after selling 59,138 shares during the period. Assenagon Asset Management S.A.’s holdings in Amgen were worth $53,406,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of AMGN. Board of the Pension Protection Fund bought a new position in shares of Amgen during the 4th quarter valued at approximately $26,000. Howard Hughes Medical Institute purchased a new stake in Amgen during the 2nd quarter valued at $32,000. Cloud Capital Management LLC bought a new stake in Amgen in the third quarter worth $34,000. Saranac Partners Ltd bought a new stake in Amgen in the third quarter worth $37,000. Finally, Holos Integrated Wealth LLC purchased a new position in Amgen during the fourth quarter worth $37,000. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

Shares of AMGN opened at $348.43 on Wednesday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company has a 50 day moving average price of $361.26 and a 200-day moving average price of $329.06. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The stock has a market capitalization of $187.83 billion, a PE ratio of 24.49, a PEG ratio of 3.47 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s revenue was up 8.6% compared to the same quarter last year. During the same period last year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AMGN. Morgan Stanley boosted their price objective on shares of Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research note on Thursday, February 5th. BMO Capital Markets increased their price objective on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the stock an “outperform” rating in a research note on Thursday, January 29th. Finally, Cantor Fitzgerald boosted their target price on Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.